drugset / Trial / NCT02308202

DOXAZOSIN FOR PTSD

NCT02308202

Phase 1 Completed 30 enrolled Baylor College of Medicine
RandomizedCrossoverDouble-blindTreatment

Summary

The aims of this study is to determine the effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy on Post Traumatic Stress Disorder. The effects of treatment with doxazosin XL 16 mg/d combined with virtual reality (VR) exposure therapy will be assessed in double-blind, placebo-controlled study. The study will enroll 30 participants. The investigators will use a within groups design in which all participants receive both placebo and doxazosin (N=16) with the order counterbalanced across participants. A second group of patients (N=16) will receive both 16mg perindopril and placebo instead of doxazosin/placebo.

Timeline

Start
2012-01
Primary completion
2014-06-30
Completion
2014-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Doxazosin Small molecule 16 mg
Comparator Perindopril Small molecule 16 mg